Company intelligence / Profile preview

Tianjin ConjuStar Biologics Co., Ltd.

Shanghai, Shanghai, Chinachinesebiotech.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has two main drug candidates in development: SC-101, a Nectin-4-targeting PDC that received IND approval from NMPA in China with an ongoing first-in-human trial (NCT06220838) and FDA IND clearance in May 2024. SC-101 was also granted Orphan Drug Designation by the FDA for esophageal cancer treatment in April 2025. SC-102, an EphA2-targeting PDC, received IND approval from NMPA in China in August 2024 with a planned Phase I trial (NCT06710158).

Therapeutic areas: Oncology
Modalities: Peptide Drug Conjugates (PDCs)Nanobody Drug Conjugates (NDCs)
Industry: Biotech

Drug pipeline

2 assets

SC-102

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tianjin ConjuStar Biologics Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianjin ConjuStar Biologics Co., Ltd..

Explore the full profile